Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Tohru Hasegawa
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Mole101on Apr 02, 2021 9:23pm
112 Views
Post# 32933055

RE:RE:RE:RE:RE:RE:Tohru Hasegawa

RE:RE:RE:RE:RE:RE:Tohru Hasegawa

Are you aware of every interview or promotional video that's put out by AGN? I'm sure they fallowed the NR , maybe added flowers around the three main points that were presented but they are well awere about not adding new information that is not officially made public first . C Moreau had made that clear in more than one interview I watched 

quote=Laliberte2020]
I do read on all platforms so yes I do know now and I don't know if the information given on biopub is considered legal since it is not public but it's certainly not ethical. Mole, apart from your love story with bithorse, you agree with management giving out complementary informations about a very short and incomplete data report to a few privileged biopub subscribers!?[/quote]
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities